Stephen Houston

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Robert Paridaens, Laura Biganzoli, P.F. Bruning et al. · Journal of Clinical Oncology · 2000 · 364 citations

Medicine, Oncology, Pharmacology +9

Loss of the Martian atmosphere to space: Present-day loss rates determined from MAVEN observations and integrated loss through time

B. M. Jakosky, D. A. Brain, M. Chaffin et al. · Icarus · 2018 · 336 citations · Full text

Natural Sciences, Earth Sciences, Meteorology +8

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

Stephen Houston, T.A. Plunkett, D M Barnes et al. · British Journal of Cancer · 1999 · 220 citations · Full text

Medicine, Endocrinology, Oncology +16

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

Stephen R.D. Johnston, Tamas Hickish, Stephen Houston et al. · Journal of Clinical Oncology · 2003 · 196 citations

Medicine, Oncology, Pharmacology +16

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Nancy U. Lin, Eric P. Winer, Duncan Wheatley et al. · Breast Cancer Research and Treatment · 2012 · 194 citations · Full text

Medicine, Oncology, Pharmacology +17